Showing results (41-50 of 128) with videos related to
Sort By:
Pageof 13
Clinical Lung Cancer|January 12, 2008
Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separationChristopher M Mahaffey, Angela M Davies, Primo N Lara, et al.Clinical Lung Cancer|January 1, 2017
Preclinical Evaluation of MET Inhibitor INC-280 With or Without the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Non-Small-Cell Lung CancerMatthew S Lara, William S Holland, Danielle Chinn, et al.Lung Cancer (Amsterdam, Netherlands)|August 23, 2022
The evolving role of liquid biopsy in lung cancerUmberto Malapelle, Pasquale Pisapia, Francesco Pepe, et al.Clinical Lung Cancer|October 27, 2015
Disease Control Rate at 8 Weeks Predicts Subsequent Survival in Platinum-Treated Extensive Stage Small-Cell Lung Cancer: Results From the Southwest Oncology Group (SWOG) DatabasePrimo N Lara, James Moon, Mary W Redman, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 19, 2010
Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097)Suresh S Ramalingam, Chandra P Belani, Philip C Mack, et al.American Journal of Clinical Oncology|June 3, 2009
A phase ii study of gemcitabine and capecitabine in patients with advanced renal cell cancer: Southwest Oncology Group Study S0312Peter J Van Veldhuizen, Michael Hussey, Primo N Lara, et al.The Prostate|January 26, 2007
GCP-mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor-dependent and -independent mechanismsClifford G Tepper, Ruth L Vinall, Christopher B Wee, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 23, 2015
SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM)Sai-Hong Ignatius Ou, James Moon, Linda L Garland, et al.Investigational New Drugs|October 23, 2010
A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trialTianhong Li, Scott D Christensen, Paul H Frankel, et al.Kidney Cancer (Clifton, Va.)|March 12, 2019
Randomized Phase 2 Study of Trebananib (AMG 386) with or without Continued Anti-Vascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma Who Have Progressed on Bevacizumab, Pazopanib, Sorafenib, or Sunitinib - Results of NCI/CTEP Protocol 9048Thomas J Semrad, Susan Groshen, Chunqiao Luo, et al.Pageof 13